GLP-2 dose-dependently inhibits bone resorption (measured as CTX-I) with only minimal effects on bone formation (measured as OCN or P1NP) in healthy postmenopausal women. Four months of GLP-2 treatment increases hip BMD in postmenopausal women with bone loss. GLP-2RA (teduglutide) increased total body BMC but not lumbar spine or hip BMD in SBS patients. This evidence concerns the gene GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.